The FDA recently approved canaglifozin (Invokana) tablets to improve glycemic control in adults with type 2 diabetes, along with diet and exercise. ... The FDA is requiring five postmarketing studies: a cardiovascular outcomes trial; an enhanced
The FDA is investigating reports of possible increased risk of pancreatitis and precancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. ... The FDA has asked the researchers to provide the methodology used to collect and
The first generic version of pioglitazone hydrochloride (Actos) and a new indication for ranibizumab injection (Lucentis) were recently announced by the FDA. ... In addition, ranibizumab injection (Lucentis) received FDA approval for a new indication to
A combination of phentermine and topiramate extended-release (Qsymia) was recently approved by the FDA as an addition to a reduced-calorie diet and exercise for chronic weight management.
The FDA is requiring safety labeling changes for fluoroquinolones to strengthen warnings that the antibiotics may cause significant decreases in blood glucose levels, as well as certain mental health side effects, ... The new label changes will add an
The FDA is requiring postmarketing studies related to pediatric use, risks of MTC, and cardiovascular outcomes. ... The most common side effects are diarrhea, nausea, and injection site reactions, according to an FDA press release.
Alogliptin (Nesina) and two new combination drugs (alogliptin and metformin hydrochloride [Kazano] and alogliptin and pioglitazone [Oseni]) were approved by the FDA to improve blood glucose control in adults with type ... The FDA is requiring five
The FDA provided recommendations to patients, caregivers, and clinicians on the proper use of both standard and safety pen needles to inject medicines in a Sept.
The FDA approved a new indication for liraglutide to reduce the risk of myocardial infarction, stroke, and cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. ... The FDA recently approved a new indication for
The FDA has identified 12 cases of necrotizing fasciitis of the perineum or Fournier's gangrene. ... The FDA warned on Aug. 29 that cases of a rare, serious infection of the genitals and surrounding area have been reported in patients taking